Efficacy and Safety of Donepezil in Patients With Alzheimer’s Disease in Assisted Living Facilities
Authors:
Open Access
- 17 June 2010
- journal article
- clinical trial
- Published by SAGE Publications in American Journal of Alzheimer's Disease and Other Dementias®
- Vol. 25 (6) , 483-489
Abstract
The aim of this 12-week, open-label study was to determine the safety and efficacy of donepezil in participants with Alzheimer’s disease (AD) residing in assisted living facilities (ALFs). Participants received 5 mg donepezil daily for 6 weeks followed by 10 mg daily for 6 weeks. Primary and secondary outcomes were change from baseline in Mini-Mental State Examination (MMSE) and Neuropsychiatric Inventory 8 (NPI-8) scores, respectively. Safety was assessed by adverse events (AEs) and laboratory tests. Of the 97 participants, 76 completed the study. Mean MMSE score (18.7 at baseline) improved 1.8 points (P < .0001) at study end. Total NPI-8 score improved 1.8 points (P = .043). The most frequent AEs were nausea and diarrhea. Donepezil improved cognition and behavior and was safe and well tolerated. The results suggest a need for proactive screening and diagnosis of AD and support the value of treatment and use of donepezil in participants residing in ALFs.Keywords
This publication has 26 references indexed in Scilit:
- Outcome of Alzheimer's Disease: Potential Impact of Cholinesterase InhibitorsThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2006
- Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled studyThe Lancet, 2006
- Evaluation of Demographics and Medication Use in Patients with Dementia in Assisted Living and Skilled Nursing FacilitiesThe Consultant Pharmacist, 2005
- Underrecognition of Cognitive Impairment in Assisted Living FacilitiesJournal of the American Geriatrics Society, 2005
- Alteration of a Clinically Meaningful Outcome in the Natural History of Alzheimer's Disease by Cholinesterase InhibitionJournal of the American Geriatrics Society, 2004
- The Maryland Assisted Living Study: Prevalence, Recognition, and Treatment of Dementia and Other Psychiatric Disorders in the Assisted Living Population of Central MarylandJournal of the American Geriatrics Society, 2004
- Impact of Rivastigmine Use on the Risk of Nursing Home Placement in a US SampleCNS Drugs, 2004
- Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's DiseaseJournal of the American Geriatrics Society, 2003
- Efficacy of Donepezil on Maintenance of Activities of Daily Living in Patients with Moderate to Severe Alzheimer's Disease and the Effect on Caregiver BurdenJournal of the American Geriatrics Society, 2003
- Cholinesterase inhibitor treatment alters the natural history of Alzheimer's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2002